Finding Specialists and Paying for Services
- Introduction to Clinical Trials
- Research Findings
- Studies Enrolling Patients
- Research Collaborations
NCT01311713
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
Study identifier:
NCT01311713
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
CEP-9722 (Cephalon)
Eligibility:
- Open to males or females who’s disease has progressed following at least 1 prior standard chemotherapy regimen.
Part II: Documented deficiency in DNA Repair Pathway (BRCA1/2) or prostate, breast, or gastric cancer
Type of study:
Phase I/II
Treatment:
- Patients receive CEP-9722 administered daily or twice-daily for six 28-day cycles.
Study site:
Michigan
Henry Ford Health System Protocol Review Committee
Detroit, Michigan, United States, 48202
Contact: 1-877-237-4879 (Cephalon)
Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Contact: 1-877-237-4879 (Cephalon)
Page updated 11/30/11
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.